NCT00071981 2023-06-28
Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma
Eastern Cooperative Oncology Group
Phase 2 Completed
Clinical Trials
7 trialsNCT00118274 2021-04-20
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
University of Virginia
Phase 1/2 Completed
NCT00398138 2016-03-02
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00706992 2015-10-28
Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00003224 2014-11-20
Vaccine Therapy in Treating Patients With Metastatic Melanoma
University of Virginia
Phase 1 Completed
NCT00001703 2014-07-25
Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00091273 2014-06-20
Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer
University of Virginia
Phase 1 Completed